Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital grows, but more slowly than its trailing trend

Q1 FY2026 change in working capital of $13.69M (cash outflow) rose 99.1% year over year, behind the +725.2% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +212.4% a year.

Context

  • Change in working capital amounted to 234.0% of revenue in FY2025, up 173.8 pp from a year earlier.
  • Change in working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +99.1% toward the trailing-twelve-month pace of +725.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.69M-136.9% QoQ
Last fiscal yearDec 2025
$28.41M+573.8% YoY
LTMMar 2026
$21.6M+725.2% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+99.1%——
1 year+573.8%——
3-year CAGR+212.4%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
28.41M USD
Year-over-year change
+573.8%
4-year CAGR
+67.3%

Change in Working Capital vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +725.2% is the 2nd highest of 11, against a peer median of +68.0%.
  • Change in working capital amounts to 129.2% of revenue for PRLD, versus a peer median of 80.1%.
PRLD Competitors
Change in Working Capital for PRLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$34.76M USD+146.8%+80.5%50.2%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$31.04M USD-3.9%—110.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$21.6M USD+725.2%+212.4%129.2%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$13.05M USD+2413.5%+184.4%39.9%
IVAInventiva S.A.FY2025€6.42M EUR+282.2%+4.0%143.1%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$3.94M USD-31.6%-51.0%35.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$3.6M USD-53.4%+42.5%1601.8%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$2.27M USD+139.8%——
PYXSPyxis Oncology, Inc.LTM Mar 2026$2.15M USD-59.7%-24.4%15.5%
IMRXImmuneering CorporationLTM Mar 2026$1.66M USD-293.7%+30.6%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$1.57M USD+169.6%—2652.5%
Peer median (excluding PRLD) —+68.0%+30.6%80.1%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Depreciation & Amortization915K1.32M1.17M1.77M1.34M
Deferred Income Tax00000
Stock-Based Compensation20.93M25.14M25.62M21.35M11.91M
Change in Working Capital3.63M932K(10.48M)4.22M28.41M
Accounts Receivables00000
Inventory00000
Accounts Payables3.9M(347K)(2.27M)3.31M(3.92M)
Other Working Capital(278K)1.28M(8.21M)911K32.33M
Other Non-Cash Items2.69M4.31M(1.54M)(3.05M)1.53M
Operating Cash Flow(83.53M)(83.73M)(107.06M)(102.89M)(56.3M)
Capital Expenditures(2.32M)(3.02M)(3.51M)(764K)(67K)
Acquisitions (Net)00000
Purchases of Investments(261.48M)(119.22M)(221.63M)(52.69M)(100.87M)
Sales of Investments0203.93M190.5M143.65M154.39M
Other Investing Activities00000
Investing Cash Flow(263.8M)81.69M(34.65M)90.19M53.46M
Debt Repayment000(395K)(208K)
Common Stock Issued161.42M815K135.73M329K25.04M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.47M0664K(54K)(17K)
Financing Cash Flow164.9M815K136.4M(120K)24.82M
Effect of Forex Changes00000
Net Change in Cash(182.44M)(1.22M)(5.31M)(12.82M)21.97M
Free Cash Flow(85.85M)(86.75M)(110.58M)(103.65M)(56.37M)

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.